This site is intended for health professionals only

At the heart of general practice since 1960

pul jul aug2020 cover 80x101px
Read the latest issue online

Independents' Day

MHRA halts recruitment to primary care hydroxychloroquine trial over death reports

Recruitment to an arm of the PRINCIPLE trial - the trial investigating coronavirus (Covid-19) treatments via GP practices - has been halted following concerns about the safety of hydroxychloroquine.

Nearly 800 GP practices across the UK are now recruiting patients onto the trial, led by the University of Oxford, but the World Health Organisation (WHO) has initiated the temporary suspension of global trials that include hydroxychloroquine. 

This comes as data from a study published in the Lancet revealed a higher mortality rate in Covid-19 patients treated with hydroxychloroquine - a drug that is most commonly used as an antimalarial.

Professor Chris Butler, lead investigator of the PRINCIPLE trial via the University of Oxford's Nuffield Department of Primary Care Health Sciences, said: ‘The Medicines and Healthcare products Regulatory Authority (MHRA) has instructed the PRINCIPLE trial of community-based treatments for Covid-19 illness to pause recruitment into its hydroxychloroquine arm. This follows publication of an observational study of hospitalised patients in the Lancet on 22 May 2020.

‘We have therefore temporarily suspended recruitment into the hydroxychloroquine arm of PRINCIPLE. We are working with the MHRA to share as much information as possible to achieve a better understanding of the situation.'

He went on to explain that PRINCIPLE 'is a flexible, platform trial of interventions suitable for use in the community that may prevent hospitalisation and speed recovery from Covid-19 illness'.

'In keeping with the generic, flexible trial design, we will continue to evaluate other treatments for Covid-19-like-illness in primary care. The safety of trial participants has always been paramount in PRINCIPLE. Those at greater risk of adverse reactions to study medicines are excluded from taking part.’

Other trials into hydroxychloroquine were also halted, including the World Health Organisation's 'solidarity' trial.

In a media briefing, WHO director-general Dr Tedros Adhanom Ghebreyesus said: ‘The executive group has implemented a temporary pause of the hydroxychloroquine arm within the solidarity trial while the safety data is reviewed by the data safety monitoring board.’

The WHO’s solidarity trial was launched to assess the safety and efficacy of four treatment options against Covid-19, including hydroxychloroquine.

Last week, the study in the Lancet analysed data from nearly 15,000 patients with Covid-19 who received the drug alone or in combination with antibiotics, against a control group of 81,000 who did not receive it.  

It found a higher risk of abnormal heartbeats, or arrhythmias, and mortality in patients with Covid-19 treated with hydroxychloroquine.

Dr Ghebreyesus continued: ‘On Friday, the Lancet published an observational study on hydroxychloroquine and chloroquine and its effects on Covid-19 patients that have been hospitalised.

‘The authors reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.’

Hydroxychloroquine was developed as an antimalarial drug, but is also used to treat conditions like lupus and arthritis.

US President Donald Trump has said he has been taken hydroxychloroquine, following public hype about it as a potential Covid-19 treatment.

Other studies published this month also suggested that hydroxychloroquine has no effect on the survival rate of Covid-19 patients, and might even increase the risk of adverse effects.

Another recent study found that renin-angiotensin aldosterone system inhibitors – taken by some patients with hypertension – do not impact the severity of Covid-19.

The PRINCIPLE trial is one of several trials supported by the UK Government's bid to find treatments for Covid-19. They also include the Recovery trial in hospital environments and Remap-Cap trial in intensive care. 

Previously, NHS England 'strongly discouraged' GPs from prescribing antimalarials while clinical trials into Covid-19 are ongoing.

Meanwhile, antiviral drug Remdesvir this week became the first drug to be approved for treatment of Covid-19 patients in the UK, after it was found to reduce the length symptoms persist.

Readers' comments (2)

  • Can you not recruit Donald Trump? I think he could be put in the double dose arm of the trial.....perhaps you've got the doses wrong??? Maybe thats why its not working.... or perhaps you need to add bleach and put him under his sunbed to get it to work????

    Unsuitable or offensive? Report this comment

  • Vinci Ho

    (1)What is interesting here is how the philosophy of the hitherto world of science conducting itself.l:
    The article stated clearly in the Discussion section :
    ‘’The use of hydroxychloroquine or chloroquine in COVID-19 is based on widespread publicity of small, uncontrolled studies, which suggested that the combination of hydroxychloroquine with the macrolide azithromycin was successful in clearing viral replication.’’
    (2)While these two groups of drug are well known for their benefits and side effects , especially the latter with QT prolongation common to both chloroquine/hydroxychloroquine and marcolides , the initial acceptance and insouciance of using these drugs so early in the pandemic crisis was phenomenal.
    On the contrary , the controversy of whether face masks should be worn more liberally continues up to now . Masks are certainly not the whole answer but at the same time ,relatively and potentially much less harmful especially if social distancing deems practically impossible in circumstances .
    (3)We are now in a phase of the pandemic when the social and economic outcomes are taking the main focus of attention instead . It is difficult to imagine taking a drug (if ever proven ‘effective’) can take the priority over a simple change in our daily social habit .

    Unsuitable or offensive? Report this comment

Have your say